Virtual lock-and-key approach: The in silico revival of Fischer model by means of molecular descriptors

European Journal of Medicinal Chemistry

Volumn 46, Issue 9, 2011, Pages 4274-4280

  Lauria, Antonino ^a   Tutone, Marco ^a   Almerico, Anna Maria ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Biological target; Drugs re purposing; Inhibitor; Lock and key; Molecular descriptors

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ABELSON KINASE; ADENOSINE A1 RECEPTOR; ALDEHYDE REDUCTASE; ALDOSTERONE SYNTHASE; ANDROGEN RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; AROMATASE; AURORA A KINASE; BLOOD CLOTTING FACTOR 10A; CARBONATE DEHYDRATASE I; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE IV; CASPASE 3; CHECKPOINT KINASE 1; CHYMOTRYPSIN; COLLAGENASE; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CYCLIN DEPENDENT KINASE; DELTA OPIATE RECEPTOR; DIHYDROFOLATE REDUCTASE; DIPEPTIDYL CARBOXYPEPTIDASE; DOPAMINE TRANSPORTER; ESTROGEN RECEPTOR ALPHA; GHRELIN RECEPTOR; INTERLEUKIN 1BETA CONVERTING ENZYME; LEGUMAIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN BCL 2; PROTEIN BCL X;

ARTICLE; CHEMICAL STRUCTURE; FISCHER MODEL; MOLECULAR BIOLOGY; MOLECULAR MODEL; MOLECULAR WEIGHT; VIRTUAL LOCK AND KEY APPROACH;

CHEMISTRY, PHARMACEUTICAL; MODELS, CHEMICAL; SOFTWARE;

EID: 80052918947     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.06.033     Document Type: Article

References (35)

1. E. Fischer Influence of the configuration on the action of the enzymes Ber. Dtsch. Chem. Ges. 27 1894 2985 2993
2. Nobel Foundation Nobel Lectures Including Presentation Speeches and Laureates Biographies, 1901-1921 1966 Elsevier Amsterdam 15 39
3. E. Fischer Faraday lecture on "synthetical chemistry in its relation to biology" J. Chem. Soc. (Lond.) 91 1907 1747 1765
4. E. Fischer Bedeutung der Stereochemie fur die Physilogie Hoppe-Seyler's Z. Physiol. Chem. 26 1898 82 83
5. R.T. Peterson Chemical biology and the limits of reductionism Nat. Chem. Biol. 2008 635 638
6. I. Nobeli, A.D. Favia, and J.M. Thornton Protein promiscuity and its implications for biotechnology Nat. Biotechnol. 27 2009 157 167
7. D. Marona-Lewicka, and D.E. Nichols Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action Pharmacol. Biochem. Behav. 87 2007 453 461
8. D. Marona-Lewicka, and D.E. Nichols WAY 100635 produces discriminative stimulus effects in rats mediated by dopamine D4 receptor activation Behav. Pharmacol. 20 2009 114 118
9. B.L. Roth, D.J. Sheffler, and W.K. Kroeze Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nat. Rev. Drug Discov. 3 2004 353 359
10. J. Bajorath Computational analysis of ligand relationships within target families Curr. Opin. Chem. Biol. 12 2008 352 358
11. T.I. Oprea, A. Tropsha, J.L. Faulon, and M.D. Rintoul Systems chemical biology Nat. Chem. Biol. 3 2007 447 450
12. D.J. Newman Natural products as leads to potential drugs: an old process or the new hope for drug discovery? J. Med. Chem. 51 2008 2589 2599
13. M.G. Siegel, and M. Vieth Drugs in other drugs: a new look at drugs as fragments Drug Discov. Today 12 2007 71 79
14. D.W. Young, A. Bender, J. Hoyt, E. McWhinnie, G.W. Chirn, C.Y. Tao, J.A. Tallarico, M. Labow, J.L. Jenkins, T.J. Mitchison, and Y. Feng Integrating high-content screening and ligand-target prediction to identify mechanism of action Nat. Chem. Biol. 4 2008 59 68
15. B.K. Wagner, T. Kitami, T.J. Gilbert, D. Peck, A. Ramanathan, S.L. Schreiber, T.R. Golub, and V.K. Mootha Large-scale chemical dissection of mitochondrial function Nat. Biotechnol. 26 2008 343 351
16. C.M. Krejsa, D. Horvath, S.L. Rogalski, J.E. Penzotti, B. Mao, F. Barbosa, and J.C. Migeon Predicting ADME properties and side effects: the BioPrint approach Curr. Opin. Drug Discov. Dev. 6 2003 470 480
17. J. Hert, P. Willett, D.J. Wilton, P. Acklin, K. Azzaoui, E. Jacoby, and A. Schuffenhauer Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures Org. Biomol. Chem. 2 2004 3256 3266
18. J. Hert, P. Willett, D.J. Wilton, P. Acklin, K. Azzaoui, E. Jacoby, and A. Schuffenhauer Comparison of fingerprint-based methods for virtual screening using multiple bioactive reference structures J. Chem. Inf. Comput. Sci. 44 2004 1177 1185
19. M. Whittle, V.J. Gillet, P. Willett, A. Alex, and J. Loesel Enhancing the effectiveness of virtual screening by fusing nearest neighbor lists: a comparison of similarity coefficients J. Chem. Inf. Comput. Sci. 44 2004 1840 1848
20. J. Hert, P. Willett, D. Wilton, P. Acklin, K. Azzaoui, E. Jacoby, and A. Schuffenhauer New methods for ligand-based virtual screening: use of data fusion and machine learning to enhance the effectiveness of similarity searching J. Chem. Inf. Model. 46 2006 462 470
21. M.J. Keiser, V. Setola, J.J. Irwin, C. Laggner, A.I. Abbas, S.J. Hufeisen, N.H. Jensen, M.B. Kuijer, R.C. Matos, T.B. Tran, R. Whaley, R.A. Glennon, J. Hert, K.L.H. Thomas, D.D. Edwards, B.K. Shoichet, and B.L. Roth Predicting new molecular targets for known drugs Nature 462 2009 175 181
22. Y.C. Martin, J.L. Kofron, and L.M. Traphagen Do structurally similar molecules have similar biological activity? J. Med. Chem. 45 19 2002 4350 4358
23. H. Kubinyi Similarity and biological activities BIOforum 5 3 2001 130 131
24. T. Liu, Y. Lin, X. Wen, R.N. Jorrisen, and M.K. Gilson Binding DB: a web-accessible database of experimentally determined protein-ligand binding affinities Nucleic Acids Res. 35 2007 D198 D201
25. A.R. Katritzky, V.S. Lobanov, and M. Karelson Quantum-chemical descriptors in QSAR/QSPR studies Chem. Rev. 96 1996 1027 1043
26. LigPrep, Version 2.2 2005 Schrodinger, LLC New York, NY
27. Y. Rew, D.L. McMinn, Z. Wang, X. He, R.W. Hungate, J.C. Jaen, A. Sudom, D. Sun, H. Tu, S. Ursu, E. Villemure, N.P. Walker, X. Yan, Q. Ye, and J.P. Powers Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11beta-HSD1 inhibitors Bioorg. Med. Chem. Lett. 19 2009 1797 1801
28. F. Lepifre, S. Christmann-Franck, D. Roche, C. Leriche, D. Carniato, C. Charon, S. Bozec, L. Doare, F. Schmidlin, M. Lecomte, and E. Valeur Discovery and structure-guided drug design of inhibitors of 11beta-hydroxysteroid- dehydrogenase type I based on a spiro-carboxamide scaffold Bioorg. Med. Chem. Lett. 19 2009 3682 3685
29. M. Siu, T.O. Johnson, Y. Wang, S.K. Nair, W.D. Taylor, S.J. Cripps, J.J. Matthews, M.P. Edwards, T.A. Pauly, J. Ermolieff, A. Castro, N.A. Hosea, A. LaPaglia, A.N. Fanjul, and J.E. Vogel N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: discovery of PF-915275 Bioorg. Med. Chem. Lett. 19 2009 3493 3497
30. H. Wang, Z. Ruan, J.J. Li, L.M. Simpkins, R.A. Smirk, S.C. Wu, R.D. Hutchins, D.S. Nirschl, K. Van Kirk, C.B. Cooper, J.C. Sutton, Z. Ma, R. Golla, R. Seethala, M.E. Salyan, A. Nayeem, S.R. Krystek, S. Sheriff, D.M. Camac, P.E. Morin, B. Carpenter, J.A. Robl, R. Zahler, D.A. Gordon, and L.G. Hamann Pyridine amides as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 Bioorg. Med. Chem. Lett. 18 2008 3168 3172
31. D. Sun, Z. Wang, Y. Di, J.C. Jaen, M. Labelle, J. Ma, S. Miao, A. Sudom, L. Tang, C.S. Tomooka, H. Tu, S. Ursu, N. Walker, X. Yan, Q. Ye, and J.P. Powers Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) Bioorg. Med. Chem. Lett. 18 2008 3513 3516
32. X. Zhang, J.E. Tellew, Z. Luo, M. Moorjani, E. Lin, M.C. Lanier, Y. Chen, J.P. Williams, J. Saunders, S.M. Lechner, S. Markison, T. Joswig, R. Petroski, J. Piercey, W. Kargo, S. Malany, M. Santos, R.S. Gross, J. Wen, K. Jalali, Z. O'Brien, C.E. Stotz, M.I. Crespo, J.L. Diaz, and D.H. Slee Lead optimization of 4-Acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease J. Med. Chem. 51 2008 7099 7110
33. R.J. Gillespie, S.J. Bamford, A. Clay, S. Gaur, T. Haymes, P.S. Jackson, A.M. Jordan, B. Klenke, S. Leonardi, J. Liu, H.L. Mansell, S. Ng, M. Saadi, H. Simmonite, G.C. Stratton, R.S. Todd, D.S. Williamson, and I.A. Yule Antagonists of the human A(2A) receptor. Part 6: further optimization of pyrimidine-4-carboxamides Bioorg. Med. Chem. 17 2009 6590 6605
34. P.J. Gilligan, L. He, T. Clarke, P. Tivitmahaisoon, S. Lelas, Y.W. Li, K. Heman, L. Fitzgerald, K. Miller, G. Zhang, A. Marshall, C. Krause, J. McElroy, K. Ward, H. Shen, H. Wong, S. Grossman, G. Nemeth, R. Zaczek, S.P. Arneric, P. Hartig, D.W. Robertson, and G. Trainor 8-(4-methoxyphenyl)pyrazolo[1,5-a]-1,3,5- triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists J. Med. Chem. 52 2009 3073 3083
35. P.J. Gilligan, T. Clarke, L. He, S. Lelas, Y.W. Li, K. Heman, L. Fitzgerald, K. Miller, G. Zhang, A. Marshall, C. Krause, J.F. McElroy, K. Ward, K. Zeller, H. Wong, S. Bai, J. Saye, S. Grossman, R. Zaczek, S.P. Arneric, P. Hartig, D. Robertson, and G. Trainor Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists J. Med. Chem. 52 2009 3084 3092